<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37430314</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>10</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>Randomized double-blind personalized N-of-1 clinical trial to test the safety and potential efficacy of TJ-68 for treating muscle cramps in amyotrophic lateral sclerosis (ALS): study protocol for a TJ-68 trial.</ArticleTitle><Pagination><StartPage>449</StartPage><MedlinePgn>449</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">449</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-023-07424-8</ELocationID><Abstract><AbstractText Label="INTRODUCTION/AIMS" NlmCategory="OBJECTIVE">Muscle cramps are a common and often disabling symptom in amyotrophic lateral sclerosis (ALS), a devastating and incurable neurodegenerative disorder. To date, there are no medications specifically approved for the treatment of muscle cramps. Ameliorating muscle cramps in ALS may improve and sustain quality of life. A widely prescribed traditional Japanese (Kampo) medicine against muscle cramps, shakuyakukanzoto (TJ-68), has been studied in advanced liver disease, spinal stenosis, kidney failure, and diabetic neuropathy. The Japanese ALS Management Guideline mentions TJ-68 for difficult muscle cramps in ALS. Therefore, the rationale of our trial is to investigate the safety and effectiveness of TJ-68 in treating painful and disabling muscle cramps in people with ALS outside of Japan. Accordingly, we are conducting a randomized clinical trial to test the safety and efficacy of TJ-68 in participants with ALS reporting frequent muscle cramps using an innovative, personalized N-of-1 design. If successful, TJ-68 may be used for muscle cramps in a broader population of people with ALS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a two-site, double-blind, randomized personalized N-of-1 early clinical trial with TJ-68. At least 22 participants with ALS and daily muscle cramps will receive drug or placebo for 2&#xa0;weeks (one treatment period) followed by a 1-week washout in a four-period cross-over design. While the primary objective is to evaluate the safety of TJ-68, the study has 85% power to detect a one-point shift on the Visual Analog Scale for Muscle Cramps Affecting Overall Daily Activity of the Columbia Muscle Cramp Scale (MCS). Secondary outcomes include the full MCS score, a Cramp Diary, Clinical Global Impression of Changes, Goal Attainment Scale, quality of life scale and ALS functional rating scale-revised (ALSFRS-R).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The study is underway. A personalized N-of-1 trial design is an efficient approach to testing medications that alleviate muscle cramps in rare disorders. If TJ-68 proves safe and efficacious then it may be used to treat cramps in ALS, and help to improve and sustain quality of life.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">This clinical trial has been registered with ClinicalTrials.gov (NCT04998305), 8/9/2021.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mitsumoto</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-6259-8923</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Irving Medical Center, 710 West 186 St, New York, NY, 10032, USA. hm264@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheung</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Mailman School of Public Health, Columbia University, 722 W 168Th St, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oskarsson</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Jacksonville, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>Howard F</ForeName><Initials>HF</Initials><AffiliationInfo><Affiliation>Data Coordinating Center (DCC) at New York State Psychiatric Institute and Columbia University, 722 W 168Th St, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Grace E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Irving Medical Center, 710 West 186 St, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>Jinsy A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Irving Medical Center, 710 West 186 St, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Jaimin S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Jacksonville, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandes</LastName><ForeName>Joseph Americo</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Nebraska, 4242 Farnam Street, Suite 650, Omaha, NE, 68198, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McElhiney</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Columbia University Irving Medical Center and New York State Psychiatric Institute, 722 W 168Th St, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santella</LastName><ForeName>Regina M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Environmental Science, Mailman School of Public Health, Columbia University, 722 W 168Th St, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04998305</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>no number</GrantID><Agency>Tsumura and Company</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C038462">shakuyaku-kanzoh-toh</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004365" MajorTopicYN="Y">Drugs, Chinese Herbal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009120" MajorTopicYN="N">Muscle Cramp</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Kampo</Keyword><Keyword MajorTopicYN="N">Muscle cramp scale</Keyword><Keyword MajorTopicYN="N">Muscle cramps</Keyword><Keyword MajorTopicYN="N">N-of-1 trials</Keyword><Keyword MajorTopicYN="N">Personalized clinical trial</Keyword><Keyword MajorTopicYN="N">Randomized controlled study</Keyword><Keyword MajorTopicYN="N">Shakuyakukanzoto</Keyword><Keyword MajorTopicYN="N">Study protocol</Keyword><Keyword MajorTopicYN="N">TJ-68</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. Hiroshi Mitsumoto, MD, DSc has received support from NIH, SPF, ALS Association, MDA Wings, Tsumura &amp; Co., Mitsubishi-Tanabe Pharma, private donation, Wesley J. Howe Professorship and has served as a paid consultant for Eli-Lilly. Ying Kuen K. Cheung, PhD, has received support from Tsumura &amp; Co. for the current study. Bj&#xf6;rn Oskarsson, MD, has received support from Tsumura &amp; Co, serves as a consultant for MediciNova Inc., and Mitsubishi and have research funding from NINDS, Biogen, MediciNova, Cytokinetics, Mitsubishi, Calico, Sanofi, and TARGET ALS. Grace E. Jang, BA, has received support from Tsumura &amp; Co. Howard Andrews, MS, PhD, directs the core facility that receives support from Tsumura &amp; Co for data management; Dr. Andrews serves as the unblinded biostatistician. Jinsy A, Andrews MD, MS, has received research funding to her institution from Amylyx, Biogen, Cytokinetics, Novartis, MGH Foundation/Ra Pharma, Biohaven/Clene/Prilenia (Platform Trial) and has served as a consultant for AL-S Pharma, Amylyx, Apellis, Biogen, Cytokinetics, Denali, Orphazyme, Quralis Neurosense, Novartis, Sanofi, UCB, and Wave Life Sciences. Jaimin S. Shah, MD has received research funding from the Muscular Dystrophy Association, Corbus Pharmaceuticals, Argenx, MGH Foundation, Clene, and Prilenia. Joseph Americo Fernandes, Jr, MD, has received support from Tsumura &amp; Co, MGH foundation, Ra Pharma, Biohaven, Clene, Seelos Therapeutics, Prilenia, and Columbia University. Martin McElhiney, PhD, has no conflicts of interest. Regina M. Santella, PhD, directs the core facility that receives support from Tsumura &amp; Co for processing blood samples.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>11</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>23</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37430314</ArticleId><ArticleId IdType="pmc">PMC10332004</ArticleId><ArticleId IdType="doi">10.1186/s13063-023-07424-8</ArticleId><ArticleId IdType="pii">10.1186/s13063-023-07424-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347(9013):1425. doi: 10.1016/S0140-6736(96)91680-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(96)91680-3</ArticleId><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group, Edaravone ALS Study Group Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Berry JD, Ciepielewska M, Liu Y, Zambrano GS, Zhang J, Hagan M. Intravenous edaravone treatment in ALS and survival: an exploratory, retrospective, administrative claims analysis. eClinicalMedicine. 2022;4(52):101590. doi: 10.1016/j.eclinm.2022.101590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101590</ArticleId><ArticleId IdType="pmc">PMC9358426</ArticleId><ArticleId IdType="pubmed">35958519</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA Approves Oral Form for the treatment of adults with amyotrophic lateral sclerosis (ALS). 2022. www.fda.gov/drugs/news-events-human-drugs/fda-approves-oral-form-treatment-adults-amyotrophic-lateral-sclerosis-als.</Citation></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919. doi: 10.1056/NEJMoa1916945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Hendrix S, Dickson SP, Knowlton N, Macklin EA, Berry JD, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63:31. doi: 10.1002/mus.27091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27091</ArticleId><ArticleId IdType="pmc">PMC7820979</ArticleId><ArticleId IdType="pubmed">33063909</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Watkins C, Cawson M, Hendrix S, Dickson SP, Knowlton N, et al. Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: evaluating the impact of treatment crossover on outcomes. Muscle Nerve. 2022;66(2):136. doi: 10.1002/mus.27569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27569</ArticleId><ArticleId IdType="pmc">PMC9540225</ArticleId><ArticleId IdType="pubmed">35508892</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA greenlights Amylyx&#x2019;s ALS drug. 2022. www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-amylyx-als-drug-2022-09-29/. </Citation></Reference><Reference><Citation>Mitsumoto H, Chad D, Pioro E. Amyotrophic lateral sclerosis. Davis Co: Philadelphia; F. A; 1998.</Citation></Reference><Reference><Citation>Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13(11):1127. doi: 10.1016/S1474-4422(14)70129-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70129-2</ArticleId><ArticleId IdType="pubmed">25316019</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson CE, Gronseth G, Rosenfeld J, Barohn RJ, Dubinsky R, Simpson CB, et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve. 2009;39(2):137. doi: 10.1002/mus.21213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21213</ArticleId><ArticleId IdType="pubmed">19145653</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasarskis EJ, Hodskins J, St Clair WH. Unilateral parotid electron beam radiotherapy as palliative treatment for sialorrhea in amyotrophic lateral sclerosis. J Neurol Sci. 2011;308(1&#x2013;2):155. doi: 10.1016/j.jns.2011.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2011.06.016</ArticleId><ArticleId IdType="pubmed">21726879</ArticleId></ArticleIdList></Reference><Reference><Citation>Pioro EP, Brooks BR, Cummings J, Schiffer R, Thisted RA, Wynn D, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68(5):693. doi: 10.1002/ana.22093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22093</ArticleId><ArticleId IdType="pubmed">20839238</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabkin JG, Gordon PH, McElhiney M, Rabkin R, Chew S, Mitsumoto H. Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study. Muscle Nerve. 2009;39(3):297. doi: 10.1002/mus.21245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21245</ArticleId><ArticleId IdType="pubmed">19208404</ArticleId></ArticleIdList></Reference><Reference><Citation>Caress JB, Ciarlone SL, Sullivan EA, Griffin LP, Cartwright MS. Natural history of muscle cramps in amyotrophic lateral sclerosis. Muscle Nerve. 2016;53(4):513. doi: 10.1002/mus.24892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24892</ArticleId><ArticleId IdType="pmc">PMC4775451</ArticleId><ArticleId IdType="pubmed">26332705</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubbay SS, Kahana E, Zilber N, Cooper G, Pintov S, Leibowitz Y. Amyotrophic lateral sclerosis. A study of its presentation and prognosis. J Neurol. 1985;232(5):295. doi: 10.1007/BF00313868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00313868</ArticleId><ArticleId IdType="pubmed">4056836</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephens HE, Joyce NC, Oskarsson B. National study of muscle cramps in ALS in the USA. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(1&#x2013;2):32. doi: 10.1080/21678421.2016.1245755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1245755</ArticleId><ArticleId IdType="pmc">PMC5575819</ArticleId><ArticleId IdType="pubmed">27978764</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, Moore D, Mozaffar T, Ravits J, Wiedau-Pazos M, Parziale N, et al. Mexiletine for muscle cramps in amyotrophic lateral sclerosis: a randomized, double-blind crossover trial. Muscle Nerve. 2018;58(1):42. doi: 10.1002/mus.26117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26117</ArticleId><ArticleId IdType="pmc">PMC6126993</ArticleId><ArticleId IdType="pubmed">29510461</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber M, Goldman B, Truniger S. Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. J Neurol Neurosurg Psychiatry. 2010;81:1135. doi: 10.1136/jnnp.2009.200642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.200642</ArticleId><ArticleId IdType="pubmed">20498181</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley WG, Anderson F, Gowda N, Miller RG, ALS Care Study Group Changes in the management of ALS since the publication of the AAN ALS practice parameter 1999. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(4):240. doi: 10.1080/14660820410021249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820410021249</ArticleId><ArticleId IdType="pubmed">15799554</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldinger R, Katzberg HD, Weber M. Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2012;(4):CD004157. 10.1002/14651858.CD004157.pub2.</Citation><ArticleIdList><ArticleId IdType="pubmed">22513921</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss MD, Macklin EA, Simmons Z, Knox AS, Greenblatt DJ, Atassi N, Mexiletine ALS Study Group et al. A randomized trial of mexiletine in ALS: safety and effects on muscle cramps and progression. Neurology. 2016;86(16):1474. doi: 10.1212/WNL.0000000000002507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002507</ArticleId><ArticleId IdType="pmc">PMC4836879</ArticleId><ArticleId IdType="pubmed">26911633</ArticleId></ArticleIdList></Reference><Reference><Citation>Swash M, Czesnik D, de Carvalho M. Muscular cramp: causes and management. Eur J Neurol. 2019;26(2):214. doi: 10.1111/ene.13799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13799</ArticleId><ArticleId IdType="pubmed">30168894</ArticleId></ArticleIdList></Reference><Reference><Citation>Ota K, Fukui K, Nakamura E, Oka M, Ota K, Sakaue M, et al. Effect of Shakuyaku-kanzo-to in patients with muscle cramps: A systematic literature review. J Gen Fam Med. 2020;21(3):56. doi: 10.1002/jgf2.302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jgf2.302</ArticleId><ArticleId IdType="pmc">PMC7260166</ArticleId><ArticleId IdType="pubmed">32489757</ArticleId></ArticleIdList></Reference><Reference><Citation>Okumi H, Koyamaet A. Kampo medicine for palliative care in Japan. Biopsychosoc Med. 2014;8(1):6. doi: 10.1186/1751-0759-8-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1751-0759-8-6</ArticleId><ArticleId IdType="pmc">PMC3901338</ArticleId><ArticleId IdType="pubmed">24447861</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumada T, Kumada H, Yoshiba M, Nakano S, Suzuki H, Tango T. Effects of Shakuyaku-kanzo-to (Tsumura TJ-68) on muscle cramps accompanying cirrhosis in a placebo-controlled double-blind parallel study. J Clin Ther Med. 1999;15:499.</Citation></Reference><Reference><Citation>Takao Y, Takaoka Y, Sugano A, Sato H, Motoyama Y, Ohta M, et al. Shakuyaku-kanzo-to (Shao-Yao-Gan-Cao-Tang) as treatment of painful muscle cramps in patients with lumbar spinal stenosis and its minimum effective dose. Kobe J Med Sci. 2015;61(5):E132.</Citation><ArticleIdList><ArticleId IdType="pubmed">27363396</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyodo T, Taira T, Takemura T, Yamamoto S, Tsuchida M, Yoshida K, et al. Immediate effect of Shakuyaku-kanzo-to on muscle cramp in hemodialysis patients. Nephron Clin Pract. 2006;104(1):c28. doi: 10.1159/000093256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000093256</ArticleId><ArticleId IdType="pubmed">16685141</ArticleId></ArticleIdList></Reference><Reference><Citation>Miura Y. Effects of Shakuyaku-kanzo-to on painful nocturnal leg cramp caused by diabetic neuropathy. Japanese J Orient Med. 1999;49(5):865.</Citation></Reference><Reference><Citation>Lee KK, Omiya Y, Yuzurihara M, Kase Y, Kobayashi H. Antinociceptive effect of paeoniflorin via spinal &#x3b1;2-adrenoceptor activation in diabetic mice. Eur J Pain. 2011;15(10):1035. doi: 10.1016/j.ejpain.2011.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpain.2011.04.011</ArticleId><ArticleId IdType="pubmed">21596599</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KK, Omiya Y, Yuzurihara M, Kase Y, Kobayashi H. Antispasmodic effect of shakuyakukanzoto extract on experimental muscle cramps in vivo: role of the active constituents of Glycyrrhizae radix. J Ethnopharmacol. 2013;145(1):286. doi: 10.1016/j.jep.2012.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2012.11.005</ArticleId><ArticleId IdType="pubmed">23164761</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaifuchi N, Omiya Y, Kushida H, Fukutake M, Nishimura H, Kase Y, et al. Effects of shakuyakukanzoto and its absorbed components on twitch contractions induced by physiological Ca2+ release in rat skeletal muscle. J Nat Med. 2015;69(3):287. doi: 10.1007/s11418-015-0890-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11418-015-0890-z</ArticleId><ArticleId IdType="pmc">PMC4460294</ArticleId><ArticleId IdType="pubmed">25783410</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadakane C, Watanabe J, Fukutake M, Nisimura H, Maemura K, Kase Y, et al. Pharmacokinetic profiles of active components after oral administration of a Kampo medicine, Shakuyakukanzoto, to healthy adult Japanese volunteers. J Pharm Sci. 2015;104(11):3952. doi: 10.1002/jps.24596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.24596</ArticleId><ArticleId IdType="pubmed">26211516</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinoshita F, Ogura Y, Suzuki Y, Hara S, Yamada A, Tanaka N, et al. Effect of orally administered shao-yao-gan-cao-tang (Shakuyaku-kanzo-to) on muscle cramps in maintenance hemodialysis patients: a preliminary study. Am J Chin Med. 2003;31(3):445. doi: 10.1142/S0192415X03001144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1142/S0192415X03001144</ArticleId><ArticleId IdType="pubmed">12943175</ArticleId></ArticleIdList></Reference><Reference><Citation>Societas Neurologica Japonica . Translation for Practical Guideline for Amyotrophic Lateral Sclerosis (ALS) 2013 5. Symptomatic Treatment CQ5&#x2013;1: How to deal with pain? Tokyo: Nankodo Co., Ltd.; 2013. p. 86.</Citation></Reference><Reference><Citation>Shefner JM, Al-Chalabi A, Baker MR, Cui LY, de Carvalho M, Eisen A, et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131(8):1975. doi: 10.1016/j.clinph.2020.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2020.04.005</ArticleId><ArticleId IdType="pubmed">32387049</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser DJ, Schultz SK, Arndt S, Benjamin ML, Fleming FW, Brems CS, et al. Capacity to provide informed consent for participation in schizophrenia and HIV research. Am J Psychiatry. 2002;159(7):1201. doi: 10.1176/appi.ajp.159.7.1201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.159.7.1201</ArticleId><ArticleId IdType="pubmed">12091200</ArticleId></ArticleIdList></Reference><Reference><Citation>Morinaga O, Ishiuchi K, Ohkita T, Tian C, Hirasawa A, Mitamura M, et al. Isolation of a novel glycyrrhizin metabolite as a causal candidate compound for pseudoaldosteronism. Sci Rep. 2018;8(1):15568. doi: 10.1038/s41598-018-33834-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-33834-9</ArticleId><ArticleId IdType="pmc">PMC6197257</ArticleId><ArticleId IdType="pubmed">30348944</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiuchi K, Morinaga O, Ohkita T, Tian C, Hirasawa A, Mitamura M, et al. 18&#x3b2;-glycyrrhetyl-3-O-sulfate would be a causative agent of licorice-induced pseudoaldosteronism. Sci Rep. 2019;9(1):1587. doi: 10.1038/s41598-018-38182-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-38182-2</ArticleId><ArticleId IdType="pmc">PMC6367500</ArticleId><ArticleId IdType="pubmed">30733510</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Chiuzan C, Gilmore M, Zhang Y, Ibagon C, McHale B, et al. A novel muscle cramp scale (MCS) in amyotrophic lateral sclerosis (ALS) Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(5&#x2013;6):328. doi: 10.1080/21678421.2019.1603310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1603310</ArticleId><ArticleId IdType="pubmed">31007059</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Miller RG, Moore DH. ALS functional rating scale-revised (ALSFRS-R) Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(Suppl 1):90. doi: 10.1080/17434470410019906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17434470410019906</ArticleId><ArticleId IdType="pubmed">15512883</ArticleId></ArticleIdList></Reference><Reference><Citation>McElhiney M, Rabkin JG, Goetz R, Katz J, Miller RG, Forshew DA, et al. Seeking a measure of clinically meaningful change in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5&#x2013;6):398. doi: 10.3109/21678421.2014.942668.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.942668</ArticleId><ArticleId IdType="pubmed">25124889</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwood K, Stolee P, Howard K, Mallery L. Use of Goal Attainment Scaling to measure treatment effects in an anti-dementia drug trial. Neuroepidemiology. 1996;15(6):330. doi: 10.1159/000109923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000109923</ArticleId><ArticleId IdType="pubmed">8930946</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts JC, Lattimore S, Recht M, Jackson S, Gue D, Squire S, et al. Goal Attainment Scaling for haemophilia (GAS-Hem): testing the feasibility of a new patient-centric outcome measure in people with haemophilia. Haemophilia. 2018;24(4):e199. doi: 10.1111/hae.13454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hae.13454</ArticleId><ArticleId IdType="pubmed">29626387</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson C, Fitzpatrick R. Reduced item set for the amyotrophic lateral sclerosis assessment questionnaire: development and validation of the ALSAQ-5. J Neurol Neurosurg Psychiatry. 2001;70(1):70. doi: 10.1136/jnnp.70.1.70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.70.1.70</ArticleId><ArticleId IdType="pmc">PMC1763474</ArticleId><ArticleId IdType="pubmed">11118250</ArticleId></ArticleIdList></Reference><Reference><Citation>Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266. doi: 10.1176/appi.ajp.2011.10111704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2011.10111704</ArticleId><ArticleId IdType="pmc">PMC3893686</ArticleId><ArticleId IdType="pubmed">22193671</ArticleId></ArticleIdList></Reference><Reference><Citation>Personal preferences for Personalised Trials among patients with chronic diseases: an empirical Bayesian analysis of a conjoint survey. 2019. https://bmjopen.bmj.com/content/10/6/e036056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7282396</ArticleId><ArticleId IdType="pubmed">32513886</ArticleId></ArticleIdList></Reference><Reference><Citation>Cellular &amp; Gene Therapy Guidances. 2022 www.fda.gov/vaccines-blood-biologics/biologics-guidances/cellular-gene-therapy-guidances and Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial Guidance for Industry, November 2022. www.fda.gov/regulatory-information/search-fda-guidance-documents/studying-multiple-versions-cellular-or-gene-therapy-product-early-phase-clinical-trial.</Citation></Reference><Reference><Citation>Woodcock J, Marks P. Drug regulation in the era of individualized therapies. N Engl J Med. 2019;381:1678. doi: 10.1056/NEJMe1911295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMe1911295</ArticleId><ArticleId IdType="pubmed">31597016</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson KW, Silverstein M, Cheung K, Paluch RA, Epstein LH. Experimental designs to optimize treatments for individuals: personalized N-of-1 trials. JAMA Pediatr. 2021;175(4):404. doi: 10.1001/jamapediatrics.2020.5801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2020.5801</ArticleId><ArticleId IdType="pmc">PMC8351788</ArticleId><ArticleId IdType="pubmed">33587109</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung, K., &amp; Mitsumoto, H. Evaluating personalized (N-of-1) trials in rare diseases: how much experimentation is enough? Harvard Data Science Review, (Special Issue 3). 2022. doi: 10.1162/99608f92.e11adff0</Citation></Reference><Reference><Citation>Kravitz RL, Duan N, eds, and the DEcIDE Methods Center N-of-1 Guidance Panel (Duan N, Eslick I, Gabler NB, Kaplan HC, Kravitz RL, Larson EB, et al. Design and implementation of N-of-1 trials: a user&#x2019;s guide AHRQ Publication No 13(14)-EHC122-EF. Rockville; Agency for Healthcare Research and Quality; 2014. http://www.effectivehealthcare.ahrq.gov/N-1-Trials.cfm.</Citation></Reference><Reference><Citation>Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9(11):617. doi: 10.1038/nrneurol.2013.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones B, Kenward MG. Design and analysis of cross-over trials. 3rd edn. Chapman &amp; Hall/CRC; 2014.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>